Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

9.24USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$9.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,599
52-wk High
$14.63
52-wk Low
$7.54

Chart for

About

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor... (more)

Overall

Beta: 4.12
Market Cap(Mil.): $435.95
Shares Outstanding(Mil.): 47.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock

* KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION

Dec 01 2017

BRIEF-Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​

* Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​ Source text: (http://bit.ly/2h9XeaC) Further company coverage:

Nov 06 2017

BRIEF-Karyopharm Q3 loss per share $0.65

* Karyopharm reports third quarter 2017 financial results and highlights recent progress

Nov 02 2017

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

Oct 12 2017

BRIEF-Karyopharm reports positive data from ongoing cancer drug study

* Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma

Sep 20 2017

BRIEF-Karyopharm appoints Michael Falvey as CFO, adds new clinical strategy

* Karyopharm appoints Michael Falvey as chief financial officer, adds new clinical strategy and human resources executives and reports inducement grant under NASDAQ listing rule 5635(c)(4)

Sep 12 2017

BRIEF-Karyopharm presents selinexor, KPT-9274 clinical data

* Karyopharm announces presentation of selinexor and KPT-9274 clinical data at the European Society of Medical Oncology 2017 annual meeting

Sep 08 2017

BRIEF-Karyopharm Therapeutics Q2 loss per share $0.64

* Karyopharm reports second quarter 2017 financial results and highlights recent progress

Aug 08 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.20 --
Roche Holding Ltd. (ROG.S) CHF245.10 +1.00
Roche Holding Ltd. (RO.S) CHF245.90 +2.50
AstraZeneca plc (AZN.L) 4,892.50 +11.50

Earnings vs. Estimates